Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

A legfontosabb adatok

Ki végzi
Herlev Hospital
Hol
Dánia1 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
15 fő, tervezett
Kezdés
2026. jún. 30.
Várható befejezés
2027. ápr. 15.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. október 14.

Ki vehet részt

Életkor
18 év – 64 év
Nem
Csak férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed informed consent by participant
  • Signed informed consent by participant’s partner (must just be obtained before the participant starts treatment at Visit 1), if applicable, regarding blood samples, data col-lection about fertility treatment as well as pregnancy and pregnancy outcome
  • 18-55 years
  • Azoospermia verified by at least 2 semen samples, average semen volume >= 1,0 ml with no identifiable sign of obstruction (samples taken at Visit -1 and at Visit 0 prior to confirmation of eligibility and dosing)
  • Serum AMH or Inhibin B level above the lower limit of quantification (LLOQ) at screening or within 6 months prior to screening
  • Testosterone < 15 nmol/L at screening or within 6 months prior to screening
  • Serum estradiol above the lower limit of normal range (48 pmol/L) at screening or within 6 months prior to screening

Ki nem vehet részt

  • Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: o Herbal products and non-routine vitamins o Insulin o Medication such as systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics
  • Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
  • Hematocrit >50% at screening or within 6 months prior to screening
  • Current abuse of steroids
  • Prior thromboembolic event within the last 24 months
  • Klinefelter or other major genetic conditions including large deletions on sex chromo-somes
  • Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
  • Severe chronic diseases requiring daily medication
  • Serum prostate specific antigen (PSA) > 3 ng/mL at screening or within 6 months prior to screening
  • Osteoporosis requiring medical treatment
  • Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
  • Average testis size > 20 mL unless obstruction has been excluded
  • TESE procedure < ½ year ago
  • LH concentration > 15 IU/L at screening
  • BMI > 45 kg/m2
  • Cardiovascular event within the last 6 months judged as significant by the investigator

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The aim of this intervention is to investigate whether the aromatase inhibitor, Leflutrozole, can improve semen quality in a subgroup of infertile men

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
A regiszteradat frissítve
2026. október 14.